Skip to main content

Course Details

Released On

March 13, 2026

Expires On

March 13, 2027

Media Type

Internet

Specialties

Cardiology, Emergency Medicine, Endocrinology, Nephrology, Pharmacy, Primary Care

Completion Time

1 hour 30 minutes

Topics

Cardiovascular Disease, Hyperkalemia, Pharmacology

Providers/Grant Support

Jointly provided by Postgraduate Healthcare Education, LLC (PHE) and Postgraduate Institute for Medicine (PIM).

This activity is supported by an educational grant from AstraZeneca.

Credits Available

  • The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact hours.
  • Designated for 0.5 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.
  • Pharmacists – 1.5 Hours (provided by Postgraduate Healthcare Education (PowerPak) PHARMACISTS please go to PowerPakhttps://www.powerpak.com/course/preamble/207977 to complete this activity.
  • Continuing Physician Assistant EducationThis activity is designated for 1.5 AAPA Category 1 CME credits.

Target Audience

This activity is designed to meet the educational needs of clinical pharmacists, specialty pharmacists, nurses, nurse practitioners (NPs), and physician assistants (PAs).

Program Overview

This activity will equip and empower clinical and specialty pharmacists, nurses, nurse practitioners (NPs), and physician assistants (PAs) with the knowledge, competence, and confidence necessary to develop and implement safe and effective hyperkalemia management plans using novel potassium binders in congruence with the latest trial data, regulatory updates, and expert consensus best practices.

Learning Objectives

At the conclusion of this activity, learners will be able to: 

  • Examine the fundamentals of potassium homeostasis, with a focus on hyperkalemia prevalence, clinical gravity, and independent risk factors
  • Evaluate the clinical trial evidentiary base and regulatory milestones for novel potassium binders, patiromer and sodium zirconium cyclosilicate
  • Develop collaborative hyperkalemia treatment plans using novel potassium binders to improve care, especially for patients with cardiovascular, kidney, and/or metabolic diseases

Faculty

Hudson pic 135

Joanna Q. Hudson, PharmD, BCPS, FASN, FCCP, FNKF

Professor
Department of Clinical Pharmacy and Translational Science & Department of Medicine (Nephrology)
The University of Tennessee Health Science Center
Nephrology Clinical Pharmacist
Methodist University Hospital
Memphis, TN

Khan pic 135

Rachel W. Khan, PharmD, BCPS, FCCP

Associate Professor
Department of Pharmacotherapy & Outcomes Science
Virginia Commonwealth University School of Pharmacy
Internal Medicine and Nephrology Pharmacist
Virginia Commonwealth University Health
Richmond, VA

Wells pic 135

Catherine Wells, DNP, ACNP, CNN-NP, FNKF

Assistant Professor, Director
Nephrology Nurse Practitioner
DOM APP Lead 
Department of Medicine, Nephrology
University of Mississippi Medical Center
Jackson, MS

Accreditation Statement

PHARMACY
Postgraduate Healthcare Education, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
UAN: 0430-9999-26-039-H01-P

Credits: 1.5 hours
Published: March 13, 2026
Expires: March 13, 2027

Type of Activity: Application
Media: Internet
Fee Information: There is no fee. This is a free continuing education activity.
Estimated time to complete activity: 90 minutes

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Postgraduate Healthcare Education. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact hours. Designated for 0.5 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.

Continuing Physician Assistant Education

Postgraduate Institute for Medicine has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until 3/13/2027. PAs should only claim credit commensurate with the extent of their participation.

Disclosures of Conflict of Interest

Dr. Hudson has disclosed that she receives honoraria for non–CME-related activities from Boehringer Ingelheim.

Dr. Khan has no relevant affiliations, no financial relationships or relationships to products or devices with a commercial interest related to the content of this activity to disclose.

Dr. Wells has disclosed that she was formerly an advisory board member for Ardelyx (relationship ended August 23, 2025) and is currently an advisory board member for Vantive.

The clinical reviewer, Steven Kheloussi, PharmD, MBA, FAMCP, has no relevant financial relationships or affiliations with any commercial interests, including products or devices, related to the content of this activity.

Susanne Kwas, MSHF, BSN, RN, Robin Carrino, and Alexia Hynes, as well as the planners, managers, and other individuals not previously disclosed who are in a position to control the content of Postgraduate Healthcare Education (PHE) continuing education activities, hereby state that they have no relevant conflicts of interest and no financial relationships or relationships to products or devices during the past 12 months to disclose in relation to this activity. PHE is committed to providing participants with a quality learning experience and to improve clinical outcomes without promoting the financial interests of a proprietary business.

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The PIM planners and others have nothing to disclose.

All relevant financial relationships have been mitigated.

Instructions for Participation and Credit

Participants must: 1) read the learning objectives and faculty disclosures; 2) view the educational activity; and 3) complete the posttest and evaluation form directly after the activity.  To answer the questions, click on your selected choice for each answer then proceed to the next question. Once completed, click on the Continue button at the bottom of the page. Your posttest will automatically be graded. If you successfully complete the posttest (score of 70% or higher), then click Finish to move on to the evaluation. Once you complete the evaluation click Submit, then your certificate will be made available immediately. Click on the Claim My Credit link, and select the appropriate certificate from the drop down. You can download and/or print the certificate for your records. If you receive a score lower than 70%, you will receive a message notifying you that you did not pass the posttest. You will have 2 opportunities to pass the posttest. To receive Credit, you must provide your date of birth and NABP number. All Credit information will be uploaded into CPE monitor within 30 days.

Disclosure of Unlabeled Use

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Postgraduate Healthcare Education, LLC, Postgraduate Institute for Medicine (PIM), or AstraZeneca. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions, and possible contraindications on dangers in use, (review of any applicable manufacturer's product information) and comparison with recommendations of other authorities.

The author, sponsor, and publisher of this continuing education activity have made all reasonable efforts to ensure that all information contained herein is accurate in accordance with the latest available scientific knowledge at the time of acceptance for publication. However, because information regarding drugs (their administration, dosages, contraindications, adverse reactions, interactions, special warnings, precautions, etc.) is subject to constant change, the reader is advised to check the manufacturer's package insert for information concerning recommended dosages and potential problems and cautions prior to dispensing or administering the drug. Special precautions should be taken when a drug is new, or highly toxic, or is unfamiliar to the dispenser or administrant. This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the US Food and Drug Administration (FDA). Neither the publisher nor sponsor promotes the use of any agent outside of approved labeling. Statements made in this activity have not been evaluated by the FDA.

Contact Information

For CME questions please contact: [email protected]